The Key Role of Pharmacists in Supporting the Landmark Changes in Asthma Management

Developed by Canadian experts in asthma care, this complimentary accredited course empowers you to assist your patients with managing this condition.




Pharmacists play a crucial role in supporting asthma control therapy in their patients. In 2022, the Global Initiative for Asthma (GINA) recommends patients receive symptom-driven prescriptions (in mild asthma) or use a daily corticosteroid-containing inhaler, to reduce the risk of severe exacerbations.

How do pharmacists continue to support and help patients navigate asthma control/management?

Take this complimentary CE course and learn how you can educate and empower your patients in this transition from two asthma experts in Canada: Dr. Anne Ellis (Professor in the Department of Medicine at Queen’s University), and Ms. Dorothy Pardalis (Clinical Pharmacist at Tilbury District Family Health Team).

Learning objectives:

Part 1:  

  • To describe the global and Canadian recommendations to help minimize over-use of short-acting beta-agonists as monotherapy and optimize controller therapy 

Part 2:  

  • Assess the level of control of an asthma patient 
  • Identify opportunities in the pharmacy to optimize asthma control for their patients 
  • List common drug therapy problems in patients with asthma that may lead to increased risk of exacerbations 
  • Apply strategies using the GINA and CTS recommendations to effectively assess, intervene, and partner with patients and their healthcare providers to improve asthma care 


Course at a glance:

  • 1.25 CEUs
  • Available until September 20, 2023
  • 1.25 hour to complete
  • Online
  • Accreditation: 8003-2020-3066-I-P
  • Completion requirement: Complete the course’s online modules and achieve a score of 70 per cent on the multiple-choice exam.

Who should take this course:

Completion requirement: Complete the course’s online modules, complete the multiple-choice exam with a score of 70 per cent or higher (two attempts), and complete the program evaluation.

Development Team:

  • Dr. Anne K. Ellis, MD (MSc FRCPC)
  • Dorothy Pardalis, RPh (BSc.Phm., CRE, CDE)
  • Lawrence Jackson, RPh (BSc.Phm, CTDP)